These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 32344183)
41. Design, synthesis, and anticancer activity of some novel 1H-benzo[d]imidazole-5-carboxamide derivatives as fatty acid synthase inhibitors. Singh S; Paul S; Brás NF; Kundu CN; Karthikeyan C; Moorthy NSHN Bioorg Chem; 2023 Sep; 138():106658. PubMed ID: 37331170 [TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors. Zhu W; Chen C; Sun C; Xu S; Wu C; Lei F; Xia H; Tu Q; Zheng P Eur J Med Chem; 2015 Mar; 93():64-73. PubMed ID: 25659752 [TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors. Zhang B; Zhang Q; Xiao Z; Sun X; Yang Z; Gu Q; Liu Z; Xie T; Jin Q; Zheng P; Xu S; Zhu W Bioorg Chem; 2020 Jan; 95():103525. PubMed ID: 31887474 [TBL] [Abstract][Full Text] [Related]
44. Molecular Modeling, Synthesis and Biological Evaluation of Sabbah DA; Hasan SE; Abu Khalaf R; Bardaweel SK; Hajjo R; Alqaisi KM; Sweidan KA; Al-Zuheiri AM Molecules; 2020 Nov; 25(22):. PubMed ID: 33207767 [TBL] [Abstract][Full Text] [Related]
45. Difuran-substituted quinoxalines as a novel class of PI3Kα H1047R mutant inhibitors: Synthesis, biological evaluation and structure-activity relationship. Zhang N; Yu Z; Yang X; Zhou Y; Tang Q; Hu P; Wang J; Zhang SL; Wang MW; He Y Eur J Med Chem; 2018 Sep; 157():37-49. PubMed ID: 30071408 [TBL] [Abstract][Full Text] [Related]
46. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors. Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536 [TBL] [Abstract][Full Text] [Related]
47. Design, synthesis, antitumor activity and theoretical calculation of novel PI3Ka inhibitors. Jin RY; Tang T; Zhou S; Long X; Guo H; Zhou J; Yan H; Li Z; Zuo ZY; Xie HL; Tang YP Bioorg Chem; 2020 May; 98():103737. PubMed ID: 32193031 [TBL] [Abstract][Full Text] [Related]
48. Design, synthesis, molecular modeling, DFT, ADME and biological evaluation studies of some new 1,3,4-oxadiazole linked benzimidazoles as anticancer agents and aromatase inhibitors. Acar Çevik U; Celik I; Işık A; Ahmad I; Patel H; Özkay Y; Kaplancıklı ZA J Biomol Struct Dyn; 2023 Mar; 41(5):1944-1958. PubMed ID: 35037830 [TBL] [Abstract][Full Text] [Related]
49. New 3-(1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one-based triazole derivatives: Design, synthesis, and biological evaluation as antiproliferative and apoptosis-inducing agents. Gaikwad NB; Bansode S; Biradar S; Ban M; Srinivas N; Godugu C; Yaddanapudi VM Arch Pharm (Weinheim); 2021 Nov; 354(11):e2100074. PubMed ID: 34346099 [TBL] [Abstract][Full Text] [Related]
50. Design and Synthesis of Coumarin Derivatives as Novel PI3K Inhibitors. Ma CC; Liu ZP Anticancer Agents Med Chem; 2017; 17(3):395-403. PubMed ID: 26902599 [TBL] [Abstract][Full Text] [Related]
51. Rational Design of a Novel 6 Shi X; Feng H; Tian H; Ma H; Pang X; Mao C; Xiang P; Xu Z; Han W; Yan Y; Chen W; Nan Y; Nan G; Hu Z; Hui L; Li C; Li Y J Med Chem; 2024 Sep; 67(17):15387-15410. PubMed ID: 39159497 [TBL] [Abstract][Full Text] [Related]
52. Synthesis and biological evaluation of solubilized sulfonamide analogues of the phosphatidylinositol 3-kinase inhibitor ZSTK474. Giddens AC; Gamage SA; Kendall JD; Lee WJ; Baguley BC; Buchanan CM; Jamieson SMF; Dickson JMJ; Shepherd PR; Denny WA; Rewcastle GW Bioorg Med Chem; 2019 Apr; 27(8):1529-1545. PubMed ID: 30850264 [TBL] [Abstract][Full Text] [Related]
53. Design, Synthesis and Biological Evaluation of 6-(Imidazo[1,2-a]pyridin-6-yl)quinazoline Derivatives as Anticancer Agents via PI3Kα Inhibition. Li M; Wang D; Li Q; Luo F; Zhong T; Wu H; Xiong L; Yuan M; Su M; Fan Y Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047827 [TBL] [Abstract][Full Text] [Related]
54. Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities. Abouzid KAM; Al-Ansary GH; El-Naggar AM Eur J Med Chem; 2017 Jul; 134():357-365. PubMed ID: 28431341 [TBL] [Abstract][Full Text] [Related]
55. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors. Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461 [TBL] [Abstract][Full Text] [Related]
56. Design, synthesis of benzimidazole tethered 3,4-dihydro-2H-benzo[e] [1, 3] oxazines as anticancer agents. Gali S; Raghu D; Mallikanti V; Thumma V; Vaddiraju N Mol Divers; 2024 Jun; 28(3):1347-1361. PubMed ID: 37233952 [TBL] [Abstract][Full Text] [Related]
57. Synthesis and antitumor activities of novel dipeptide derivatives derived from dehydroabietic acid. Huang XC; Wang M; Wang HS; Chen ZF; Zhang Y; Pan YM Bioorg Med Chem Lett; 2014 Mar; 24(6):1511-8. PubMed ID: 24565905 [TBL] [Abstract][Full Text] [Related]
58. Synthesis of benzimidazoles bearing oxadiazole nucleus as anticancer agents. Rashid M; Husain A; Mishra R Eur J Med Chem; 2012 Aug; 54():855-66. PubMed ID: 22608854 [TBL] [Abstract][Full Text] [Related]